ARTBIO is a clinical-stage radiopharmaceutical company that develops new alpha radioligand therapies (ARTs). ARTBIO's approach uses tumor-specific targets and the best alpha-precursor isotope (Pb212) to develop safe and effective therapeutics.

<p>ARTBIO is a clinical-stage radiopharmaceutical company that develops new alpha radioligand therapies (ARTs). ARTBIO&#39;s approach uses tumor-specific targets and the best alpha-precursor isotope (Pb212) to develop safe and effective therapeutics. ARTBIO is working with SpectronRx to develop a new prostate cancer therapy called AB001.</p>


ARTBIO

Radiopharmaceutical Scientist

Principal Scientist/Associate Director, Peptide Chemistry

Animal Technician

Research Associate II/Senior Research Associate, Biology

CDMO Tech Transfer Lead

Laboratory Technician

Senior Director, Preclinical

Senior Scientist / Principal Scientist, Radiobiology

Research Technician, In Vivo Biology

Thor Medical and ARTBIO Forge Strategic Supply Partnership - TipRanks

We are delighted to announce that ARTBIO has entered into a master supply agreement with Thor Medical ASA. Thor Medical will supply #thorium (Th-228) to ARTBIO for the manufacturing of Pb212 through our proprietary AlphaDirect technology to support the development of our pipeline of novel #Alpha #Radioligand #Therapies. Learn more: https://shorturl.at/l9GXl 

Thor Medical is pioneering methods to recover Th228 from existing material stockpiles rather than manufacturing it by irradiating other materials. We look forward to working closely with them in our Oslo laboratories, not far away from their production site.

#NuclearMedicine #RadioligandTherapy #Radiopharmaceuticals #Biotech #ProstateCancer #ARTs

Thor Medical and ARTBIO sign strategic long-term supply agreement for Thorium-228ARTBIO, Thor Medical | October 29, 2024


              New England Venture Capital Association Announces Nominees for the 12th Annual NEVY Awards
            

 FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer 

 Nucleus RadioPharma makes Artbio’s radiopharma assets; Minaris manufactures bluebird’s Lyfgenia 

 Nucleus RadioPharma unveils manufacturing pact with ARTBIO 

FogPharma, ARTBIO Partner To Develop Helicon-Enabled ARTs (HEARTs) - Contract Pharma


              Emanuele Ostuni - CEO, ARTBIO
            

 ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New ... 

The group I'm in at ARTBIO is growing! We are looking for a biochemist/biophysicist with some plate based assay experience (SPR or ITC experience are a plus)! Reach out if you're interested or know someone that might be a good fit! 

 https://lnkd.in/ePUZqZVk 

Apply for this job

SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States - Business Wire

 SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy ... 

Novartis, Lilly drive investor interest in radiopharmaceuticals

 Rain in Gaza: Displaced Palestinians Face Heightened ... 

Investors pour $90M onto ARTBIO's palette less than 6 months after launching - Fierce Biotech

 Artbio brings in $90M for radioactive molecules that target cancer 

Research & DevelopmentPrincipal Scientist/Associate Director, Peptide ChemistryCambridge, MA

 Artbio raises $23M to advance lead-based radioligand therapies for prostate cancer 

ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of ARTBIO's AlphaDirect™ Technology - PR Newswire

Check out this job at ARTBIO: CDMO Tech Transfer Lead

ARTBIO divulges plans for proprietary isotope manufacturing technology - Pharmaceutical Technology

 ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials 

 Fogpharma and Artbio collaborate to create new class of α-radioligand therapeutics for solid tumors 

BIO announces new CEO—Chutes & Ladders

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential - PR Newswire

 Women played a leading role in the pandemic-fueled boom in ... 

Lilly picks new head of diabetes, obesity unit—Chutes & ...

 ARTBIO’s Exclusive Strategic Collaboration with AlphaGen Therapeutics 

 ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer 

The ARTBIO team is excited to attend both the Hanson Wade Group’s 6th Annual Targeted Radiopharmaceuticals Summit Europe and the 36th Annual Piper Sandler Healthcare Conference from December 3-5!

At the Targeted Radiopharmaceuticals Summit Europe in Amsterdam, we’ll connect with industry leaders to exchange insights, explore innovative solutions, and contribute to discussions advancing radiopharmaceutical therapies. Our colleagues Vicki Jardine and Daniel Rossetto will share ARTBIO’s vision for Pb212-based #Alpha #Radioligand #Therapies (#ART).

Emanuele Ostuni is looking forward to in-depth discussions on emerging trends, connecting with experts, and gaining fresh strategies at the Piper Sandler Healthcare Conference. We hope to see you there! 

Learn more about our innovative methods and recent partnerships at https://artbio.com/

#RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine


              Radiopharmaceutical Strategies Begin To Take Shape As Field Rolls Into 2025
            

Principal Investigator Dr. Kjetil Berner from Oslo University Hospital will be presenting early clinical data on ARTBIO’s lead program, AB001, a PSMA-targeted 212Pb #Alpha #Radioligand #Therapy for metastatic castration resistant prostate cancer (#mCRPC), at the 2024 European Multidisciplinary Congress on Urological Cancers (#EMUC24).
 
The poster presentation highlights data from the Phase 0 imaging study of AB001. Gamma camera imaging following a 212Pb AB001 microdose showed tumor targeting and promising biodistribution. This early clinical research could lead to more treatment options for patients with prostate cancer in the future. View the poster here: https://lnkd.in/et7_p356
 
Be sure to stop by to learn how we are redefining cancer care by developing a new class of #Alpha #Radioligand #Therapies (#ARTs) based on the ideal isotope #Pb212.
 
#RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine #Oncology #ProstateCancer

The European Association of Nuclear Medicine (EANM) Annual Congress kicks off this Saturday and we’re thrilled to be attending! 

Join us as we explore the latest advancements in #NuclearMedicine, share insights with industry leaders, and connect with fellow innovators. Together, we can shape the future of patient care and drive meaningful change in the field. Stay tuned for updates from the event!

#EANM24 #RadioligandTherapy #Radiopharmaceuticals #Biotech

Emanuele Ostuni | Conrad Wüller | ✪ Philippe Dasse ✪ ☤ | Daniel Rossetto | Phil Ruis | Vicki Jardine | Ivana Galetic | Mohana Suppiah-Coll | Tanja Aarvak | Elisa Fiorito, Ph.D. | Vilde Yuli Stenberg | Joshua Needham-Clark | Rosa Greasley | Jordi Vall-llossera

ARTBIO, Nucleus RadioPharma Enter Manufacturing & Supply Pact - Contract Pharma

The ARTBIO team is excited to be attending several upcoming events in the coming weeks, including the William Blair Conference, the ICPO Foundation-International Centers for Precision Oncology Theranostics Summit, and the 2024 Jefferies London Healthcare Conference!

ARTBIO Chief Scientific Officer Nick Pullen will be speaking at the ICPO Summit with a first disclosure of pre-clinical data underwriting the superiority of alpha emission in a bone metastasis Prostate Cancer model, as well as clinical data from a Ph0 evaluation of AB001.

ARTBIO Chief Executive Officer Emanuele Ostuni will be joining Andy Hsieh for a fireside chat as part of the William Blair’s Innovator Series: Radiopharmaceuticals, discussing ARTBIO’s vision for Pb212-based alpha radioligand therapies and the progress the company has made since its inception.

We look forward to insightful discussions and sharing the latest updates about our approach to #Alpha #Radioligand #Therapies (#ART). Find out more about our unique approach at https://artbio.com/

#WilliamBlair #JefferiesHealthcare #RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine

Thor Medical invitation to capital markets update | Thor Medical ASA - NTB Kommunikasjon

FogPharma, ARTBIO Partner to Develop Helicon-Enabled ARTs (HEARTs) - Contract Pharma

 AlphaGen And ArtBio Form China-US Radioligand Partnership 

Excited about alpha radioligand therapies and peptide science? ARTBIO is hiring!

#radioligandtherapy #peptidechemistry #peptides #SAR #drugdevelopment

Please join us in welcoming Amra Demirovic as Chief Human Resources Officer!

Amra brings extensive experience in human resources and a proven track record of fostering inclusive workplace cultures. Amra comes to us from BeiGene, where she led HR for Europe & New Markets. Prior to that, she held key HR positions at Novartis. 

Amra loves sports and exploring the world with her son.

Welcome to the team, Amra! 

#nuclearmedicine #radioligandtherapy #radiopharmaceuticals #biotech #team

ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States - PR Newswire

SpectronRx, ARTBIO Partner on Alpha Radioligand Therapy - Contract Pharma

 Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates 

 Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities 

Radiopharma startup Artbio raises $90M in sign of field’s momentum - BioPharma Dive

ARTBIO Home Page

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities - Business Wire

 RLS expands by offering radiopharmaceutical contract ... 

 “Survivor 45” exclusive deleted scene flashes back to day 1 of ... 

Research & DevelopmentAnimal TechnicianOslo

ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline - The Pharma Letter

 ARTBIO Raises $90M in Series A Financing 

Research & DevelopmentResearch Associate II/Senior Research Associate, BiologyCambridge, MA

ARTBIO and Oslo University Hospital Announce Collaboration to Advance the Research and Development of Alpha Radioligand TherapiesARTBIO, Oslo University Hospital | June 5, 2024

 ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of ARTBIO's AlphaDirect™ Technology 

 ARTBIO: $90 Million Secured To Develop New Class Of Alpha Radioligand Therapies 

 Updated: Radiopharmaceuticals Market Predicted to Grow ... 

Nucleus RadioPharma makes Artbio’s radiopharma assets; Minaris manufactures bluebird’s Lyfgenia - Endpoints News

Artbio and 3B Pharmaceuticals to advance α-radioligand therapy for solid tumors - BioWorld Online

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of CancerARTBIO, FogPharma | May 14, 2024

Fierce Biotech Fundraising Tracker '23

www.artbio.com

Deals Report: J&J acquires Proteologix, Fog-ARTbio to develop radiotherapies - BioCentury

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer - Business Wire

Thor Medical and ARTBIO sign strategic long-term supply agreement for Thorium-228 - NTB Kommunikasjon

 AlphaGen and ArtBio Form China-US Partnership for Radioligand Therapies 

 The Week's 10 Biggest Funding Rounds: X-Energy And ... 

Norwegian biotech startup nabs $23M seed to develop radiopharmaceuticals for prostate cancer - ArcticStartup - ArcticStartup

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors - PR Newswire

 ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors 

SpectronRx, ARTBIO Partner On Alpha Radioligand Therapy - Contract Pharma

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies - PR Newswire

 FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle ... 

Artbio launches for alpha-emitting radiopharmaceuticals to treat cancer - Chemical & Engineering News

 ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products ... 

Investors pour $90M onto ARTBIO's palette 6 months after ...

Artbio raises $90M as radiopharma field finds its footing - Endpoints News

 Artbio raises $90M as radiopharma field finds its footing 

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid TumorsARTBIO, 3B Pharmaceuticals | November 14, 2024


              ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors
            

 GSK, Novartis, among winners at LSX Awards - BioProcess ... 

ARTBIO, PharmaLogic Enter Manufacturing And Supply Pact - Contract Pharma

CDMO Nucleus RadioPharma links up with ARTBIO to help produce prostate cancer candidate for clinical trials - FiercePharma

ARTBIO team members Emanuele Ostuni, Nick Pullen, and Conrad Wüller will attend the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco next month! 

We're eager to connect with industry leaders, share our progress, and explore partnerships to advance #Alpha #Radioligand #Therapies (#ART) as a transformative treatment for #Cancer.

We're also honored to have the opportunity to present our company on Thursday, January 16, at 9:00 AM as part of the conference agenda.

#JPM25 #Radiopharmaceuticals #Biotech #NuclearMedicine


ARTBIO

Business:

Drug notes:

About: